Company intelligence / Profile preview
Frontier Biotechnologies Inc.
Nanjing, Chinafrontierbiotech.com ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Commercial
01
Overview
Frontier Biotechnologies has successfully developed and commercialized Aikening (Albuvirtide), the first long-acting injectable HIV fusion inhibitor in the world, which received marketing authorization in China in 2018 and in several other countries including Ecuador, Cambodia, Malaysia, Azerbaijan and Kazakhstan[1].
- Therapeutic areas
- CardiovascularRheumatologyEndocrinologyInfectious Diseases
- Modalities
- Long-acting peptide drugstherapeutic peptide vaccine
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Beyond the preview
Go deeper on Frontier Biotechnologies Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Frontier Biotechnologies Inc..